Short-term Efficacy of Narivent® in the Treatment of Nasal Congestion
Valerio Damiani1, Angelo Camaioni1, Claudio Viti1, Giulia Schillani2, Francesca Foltran3, Antonella Silvia Scire4, Giada Morpurgo4, Dario Gregori3, *
Identifiers and Pagination:Year: 2012
First Page: 66
Last Page: 72
Publisher Id: TOMDJ-4-66
Article History:Received Date: 8/8/2012
Revision Received Date: 15/08/2012
Acceptance Date: 17/08/2012
Electronic publication date: 20/9/2012
Collection year: 2012
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Rationale and aim:
Nasal congestion is a common symptom in rhinologic diseases such as rhinosinusitis, nasal polyposis and adenoid pathology. Although various pharmacotherapy options exist, no agent is universally efficacious. The aim of this study was to evaluate the efficacy of Narivent®, an osmotically acting medical device with antioedematous and anti-inflammatory effects, in a short-term (7days) treatment.
A single-centre prospective study with a pre-post design was conducted with consecutive enrolment in an Italian Otolaryngology Department of 36 both genders patients with nasal congestion. Patients received 2 puffs of Narivent® into each nostril 2 times a day over the course of 1 week. The severity of symptoms was assessed subjectively as measured by a 0 to 10 visual analogue scale (VAS) and the presence/absence of symptoms and signs. Differences in subjective and objective severity measures before and after treatment were compared using Paired-Sample Wilcoxon Signed Rank Test.
A significant improvement after treatment (p<0.001) has been recorded for the main subjective symptoms and objective signs (overall symptom burden, nasal congestion, cephalea, turbinates hypertrophy, normal mucosa status).
Study results confirm the efficacy of Narivent® in treating nasal congestion over a 1 week period.